Ranbaxy recalls three drugs for lack of safety warnings

Failure to include updated safety warning information for three drugs has led to Ranbaxy recalls in the U.K. The drugs, which pharmacies have been asked to quarantine, are the antiviral aciclovir, anti-fungal fluconazole and analgesic oldaram, reports the Financial Express.

Under the Class 2 recall, Ranbaxy was required to take action within 48 hours of notification by the U.K.'s Medicines and Healthcare Products Regulatory Agency, the article said. It's the second U.K. recall for Ranbaxy this year. The generics-maker called back the skin infection drug isotretinoin in July after an EC suspension of marketing authorization due to bioequivalence concerns.

The current recall is due to the safety warning information being omitted from patient leaflets, according to an alert by the National Pharmacy Association. There are no product quality concerns, said a company spokesman in the story.

The recall involves one batch of each drug. All were manufactured between October 2010 and February 2011.

- here's the story
- see the National Pharmacy Association alert
- here are details of the July isotretinoin recall

Suggested Articles

A few years ago, one of our Fierce editors met a Big Pharma R&D chief for the first time. “You’re the ones with the scary name,” he joked.

AstraZeneca has signed a $750 million deal to produce up to 300 million doses of Oxford University's COVID-19 vaccine by year's end.

Racing with some COVID-19 vaccine heavyweights, Novavax has brought on a partner to manufacture adjuvant for its in-development shot.